Post Acute Medical (PAM) Accelerates Adoption of Exoskeleton Rehabilitation with Three Additional EksoNR Devices from Ekso Bi...
February 19 2020 - 8:00AM
Post Acute Medical, LLC, (PAM), a system of inpatient
rehabilitation hospitals, has acquired three additional EksoNR
devices from Ekso Bionics (Nasdaq: EKSO) to expand the availability
of exoskeleton-assisted rehabilitation to seven of its facilities.
The new EksoNR devices will be placed in Kyle and Clear Lake,
Texas and Tulsa, Oklahoma. Exoskeleton-assisted rehabilitation is
now available at five PAM locations in Texas. The device is
designed to help patients stand and walk during rehabilitation
after a stroke or spinal cord injury.
“Using EksoNR exoskeletons to help our stroke and spinal cord
injury patients learn to walk again has been transformative,” said
Anthony Misitano, PAM's President and Chief Executive Officer. “The
technology has been an integral part of our patients’ recovery and
our physical therapists are eager to integrate it into their care
of more patients. We are pleased to respond to the needs of our
patients and providers with three additional EksoNR devices.”
PAM provides inpatient rehabilitation services in 12 states
through 41 inpatient rehabilitation hospitals and long-term acute
care hospitals, as well as more than 32 outpatient physical therapy
locations. Inpatient rehabilitation hospitals are specialty
hospitals or parts of acute care hospitals that offer intensive
rehabilitation therapy. The most common conditions that may qualify
a patient for care in a rehabilitation hospital include stroke,
spinal cord injury, and brain injury.
“We are excited to see the growth of exoskeleton-assisted
rehabilitation in systems like PAM,” said Jack Peurach, Chief
Executive Officer and President of Ekso Bionics. “Using our
exoskeleton devices in rehabilitation can provide better patient
outcomes by helping patients walk farther and faster, and have
better balance outside of the device. We are thrilled that PAM is
embracing our technology and making it available to more of their
patients.”
EksoNR is the next generation EksoGT—the most clinically used
robotic exoskeleton. Developed for neurorehabilitation, EksoNR is
an intuitive exoskeleton device that empowers patients recovering
from stroke or spinal cord injury to learn to walk again with a
more natural gait. To find a location near you, please visit:
eksobionics.com/centers.
About Post Acute Medical, LLCPost Acute
Medical, LLC, (PAM) based in Enola, PA, provides post-acute health
care services through 43 long-term acute care hospitals and
inpatient rehabilitation hospitals, as well as more than 32
outpatient physical therapy locations, in 12 states. PAM is
committed to providing high-quality patient care and outstanding
customer service, coupled with loyalty and dedication of highly
trained staff, to be the most trusted source for post-acute
services in every community it serves. Our mission is to serve
people by providing compassionate, expert care and to support
recovery through education and research. Learn more
at www.postacutemedical.com.
About Ekso Bionics® Ekso Bionics® is
a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical and industrial applications. Founded in
2005, the Company continues to build upon its industry-leading
expertise to design some of the most cutting-edge, innovative
wearable robots available on the market. Ekso Bionics is the only
exoskeleton company to offer technologies that range from helping
those with paralysis to stand up and walk, to enhancing human
capabilities on job sites across the globe. The Company is
headquartered in the San Francisco Bay Area and is listed on the
Nasdaq Capital Market under the symbol “EKSO.” For more
information, visit: www.eksobionics.com or
follow @EksoBionics on Twitter.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the potential benefits of the Company’s products, including the
EksoNR, (ii) the performance or effectiveness of the Company’s
products, including the EksoNR, and (iii) the assumptions
underlying or relating to any statement described in clauses (i)
and (ii) above. Such forward-looking statements are not meant to
predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company’s current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company’s inability to obtain
adequate financing to fund the Company’s operations and necessary
to develop or enhance the Company’s technology, the significant
length of time and resources associated with the development of the
Company’s products, the Company’s failure to achieve broad market
acceptance of the Company’s products, the failure of the Company’s
sales and marketing efforts or of partners to market the Company’s
products effectively, adverse results in future clinical studies of
the Company’s medical device products, the failure to obtain or
maintain patent protection for the Company’s technology, the
failure of the Company to obtain or maintain regulatory approval to
market the Company’s medical devices, the lack of product
diversification, existing or increased competition, and the
Company’s failure to implement the Company’s business plans or
strategies. These and other factors are identified and described in
more detail in the Company’s filings with the U.S. Securities and
Exchange Commission. To learn more about Ekso Bionics please visit
the Company’s website at www.eksobionics.com or follow @EksoBionics
on Twitter. The Company does not undertake to update these
forward-looking statements.
Media Contact:Carrie Yamond
Mas917-371-2320cmas@eksobionics.com
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024